Results 101 to 110 of about 41,716 (223)
Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION
We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS
We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau‐PET.Isabella Bizzi, Arthur C. Macedo, Lydia Trudel, Joseph Therriault, Nesrine Rahmouni, Firoza Z. Lussier, Cécile Tissot, Gleb Bezgin, Étienne Aumont, Tevy Chan, Seyyed Ali Hosseini, Delphine Oliva‐Lopez, Marina Pereira Gonçalves, Guilherme Povala, Pamela C. L. Ferreira, Bruna Bellaver, Livia Amaral, Emma Ruppert, Marina Scop Medeiros, Rayan Mroué, Andréia Rocha, Kok Pin Ng, Eduardo R. Zimmer, Joseph Masdeu, Belen Pascual, Val J. Lowe, Hwamee Oh, David N. Soleimani‐Meigooni, Juan Fortea, Zahinoor Ismail, Suzanne Baker, Tharick A Pascoal, Pedro Rosa‐Neto, for the HEAD Study, Cristiano S Aguzzoli, Livia Amaral, Guilherme Bauer‐Negrini, Bruna Bellaver, Ann D Cohen, Alvaro de Oliveira Franco, Douglas T Leffa, Pamela C L Ferreira, Firoza Z Lussier, Marina S Medeiros, Rayan Mroué, Markley S Oliveira, Tharick A Pascoal, Guilherme Povala, Andréia Rocha, Matheus S Rodrigues, Emma Ruppert, Pampa Saha, Juli Singer, Carolina Soares, Dana L Tudorascu, Raphael L Tuma, Suzanne L Baker, Cécile Tissot, Hsin‐Yeh Tsai, Pedro Rosa‐Neto, Tevy Chan, Vladimir Fonov, Yasser Iturria‐Medina, Wan Lu Jia, Jesse Klostranec, Maxime Montembault, Nesrine Rahmouni, Jenna Stevenson, Karine Provost, Paolo Vitali, Selma Avdagic, Emerine Cummings, Brian A Gordon, Danielle Gray, Victoria Tate, Joseph C Masdeu, Belen Pascual, Hwamee Oh, Xiaoyang Hu, Val Lowe, David N Soleimani‐Meigooni, Juan Fortea, Arthur Toga, Tatiana Foroud +83 morewiley +1 more sourceAssociations between plasma biomarker levels and quantitative postmortem neuropathologic measures in Alzheimer's disease and related dementias
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION
Validation of Alzheimer's disease blood‐based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations between BBMs and quantitative postmortem neuropathology in 124 participants from the ...Celia R. Bianco, Neus Rabaneda‐Lombarte, Hadia Fatima, Johanna Celedon, Derek H. Oakley, Steven E. Arnold, Pia Kivisäkk, Alberto Serrano‐Pozo +7 morewiley +1 more sourceCell‐based polygenic risk scores predict clinical progression and prioritize network‐based therapeutic targets in Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND
Late‐onset Alzheimer's disease (AD) exhibits substantial biological heterogeneity. We developed a framework linking cell‐type–specific polygenic risk profiles to precision medicine in AD. METHODS
Cell‐based polygenic risk scores (cbPRSs) derived from single‐nucleus RNA‐seq co‐expression networks were evaluated in Alzheimer's Disease Nathan Sahelijo, Priya Rajagopalan, Lu Qian, Rufuto Rahman, Daniel Goldstein, Sophia I. Thomopoulos, David A. Bennett, Lindsay A. Farrer, Thor D. Stein, Li Shen, Heng Huang, Kwangsik Nho, Andrew J. Saykin, Christos Davatzikos, Paul M. Thompson, Julia TCW, Gyungah R. Jun +16 morewiley +1 more sourceIncreased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss
Alzheimer’s Research & TherapyAstrogliosis plays an important role in Alzheimer’s disease(AD). We characterized glial fibrillary acidic protein(GFAP) and purinergic P2X7 receptor(P2X7R) alterations in AD and their associations with amyloid-β levels, tau pathology and synaptic density.Cinzia A. Maschio, Oscar Moreno, Junlong Wang, Upasana Maheshwari, Annika Keller, Uwe Konietzko, Daniel Razansky, Agneta Nordberg, Axel Rominger, Christoph Hock, Jordi Llop, Roger M. Nitsch, Ruiqing Ni +12 moredoaj +1 more sourcePlasma eMTBR‐tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION
The concentration of endogenous tau microtubule‐binding region containing residue‐243 in plasma (eMTBR‐tau243) has been proposed to be a sensitive biomarker of tangle pathology in Alzheimer's disease (AD). We assessed eMTBR‐tau243 and phosphorylated tau217 (p‐tau217) with tau and Aβ‐positron emission tomography (PET) across ...Jennifer L. Whitwell, Jerusha G. Bhaskaran, Ryota Satoh, Jonathan Graff‐Radford, Mary M. Machulda, Val J. Lowe, Michelle M. Mielke, Dennis W. Dickson, Shin‐Cheng Tzeng, John Bui, Philip B. Verghese, Tim West, Venky Venkatesh, Keith A. Josephs +13 morewiley +1 more sourceEntorhinal grid-like codes for visual space during memory formation
Nature CommunicationsEye movements, such as saccades, allow us to gather information about the environment and, in this way, can shape memory. In non-human primates, saccades are associated with the activity of grid cells in the entorhinal cortex.Luise P. Graichen, Magdalena S. Linder, Lars Keuter, Ole Jensen, Christian F. Doeller, Claus Lamm, Tobias Staudigl, Isabella C. Wagner +7 moredoaj +1 more sourceProteomic dysregulation associated with cerebral amyloid angiopathy
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION
Cerebral amyloid angiopathy (CAA) is characterized by impaired vascular amyloid‐β clearance, distinct from Alzheimer's disease (AD), underscoring the need to clarify its molecular basis for predicting therapy‐related amyloid‐related imaging abnormalities. METHODS
We analyzed post‐mortem brain proteomics from Religious Orders Study Sang‐Won Han, Young Ho Park, Jung‐Min Pyun, Paula J. Bice, David A. Bennett, Shahram Oveisgharan, Andrew J. Saykin, SangYun Kim, Kwangsik Nho +8 morewiley +1 more sourceSpatiotemporal heterogeneity and dynamic evolution of microglial glucose metabolic reprogramming in Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract
Alzheimer's disease (AD) is accompanied by persistent disturbances in brain energy metabolism, and microglial glucose metabolic reprogramming constitutes an important link among pathological protein deposition, neuroinflammation, and impaired clearance.Yuan Chen, Fuyao Li, Junlei Zhang, Mingqing Wei, Jingnian Ni, Ting Li, Lulu Yao, Jinzhou Tian, Jing Shi +8 morewiley +1 more sourceNetwork‐dependent remote effects and local tau burden jointly shape neuronal dysfunction in Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND
Tau pathology in Alzheimer's disease (AD) propagates along the brain's connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to tau‐harboring epicenters. METHODS
One hundred thirty‐one amyloid‐positive individuals underwent dynamic [Lukas Frontzkowski, Sebastian Roemer‐Cassiano, Johannes Gnörich, Daniel Janowitz, Hannah Eyob, Katharina Probst, Dario Dhoqina, Anna Dewenter, Anna Steward, Zeyu Zhu, Madleen Klonowski, Fabian Hirsch, Davina Biel, Melina Paulus, Jonathan Vöglein, Sonja Schönecker, Boris‐Stephan Rauchmann, Carolin Kurz, Carolin Koriath, Jan Häckert, Sophia Stöcklein, Carla Palleis, Robert Perneczky, Johannes Levin, Katharina Buerger, Rudolf A. Werner, Günter Höglinger, Matthias Brendel, Nicolai Franzmeier +28 morewiley +1 more source